In recent years, the pharmaceutical industry has been calling for a reduction in taxes and fees. After the implementation of policies such as replacing business tax with value-added tax and the two invoice system, pharmaceutical companies have felt more direct financial and tax pressure. On March 4, Zhao Yixin, a deputy to the National People's Congress and chairman of Shandong Xinhua Medical Devices Co., Ltd., proposed at the "two sessions" of the medical sector representatives' forum that at this stage, the enterprise value-added tax rate is high, the enterprise business burden is heavy, and in the face of opportunities and challenges, the government needs more encouragement and support. Public information shows that there is currently a lack of financial and tax incentives for pharmaceutical R&D investment. Although the government has incentive policies for addi...